HDAC1 and acute myeloid leukemia: Chidamide, a selective HDAC1/2/3/10 inhibitor, induces oxidative stress-mediated DNA damage and demonstrates efficacy in R/R AML, which has been approved by the National Medical Products Administration (NMPA) in China (Wang et al., 2020).